To: 5.1.2e @mscbs.es[5.1.2e @mscbs.es]
From: 5.1.2e)
Sent: Mon 8/24/2020 2:18:31 PM
Subject: RE: Remdesivir
Received: Mon 8/24/2020 2:18:31 PM

Dear Patricia,

In the Netherlands we have still some access to doses from the ESI program 5.1.1c 5.1.1c 5.1.1c We have not started any action for a compulsory license. However, it is something to consider.
Gilead has provided licenses to generic companies for distribution to low- and middle income countries, so why not urge them to scale production also for other countries together with the generic industry.
What are the plans in Spain for that?

All the Best
5.1.2e

Gilead has signed non-exclusive voluntary licensing agreements with generic pharmaceutical manufacturers based in Egypt, India and Pakistan to further expand supply of remdesivir. The agreements allow the companies – Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; Eva Pharma; Ferozsons Laboratories; Hetero Labs Ltd.; Jubilant Lifesciences; Mylan; Syngene, a Biocon company; and Zydus Cadila Healthcare Ltd. – to manufacture remdesivir for distribution in 127 countries. The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access. The regulatory approval status of remdesivir varies by country, and the distribution of remdesivir within each country listed below is subject to local laws and regulations.

Under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly. The licensees also set their own prices for the generic product they produce. The licenses are royalty-free until the World Health Organization declares the end of the Public Health Emergency of International Concern regarding COVID-19, or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent COVID-19, whichever is earlier.

Van: 5.1.2e @mscbs.es < 5.1.2e @mscbs.es>
Verzonden: zondag 23 augustus 2020 17:12
Aan: 5.1.2e) < 5.1.2e @minvws.nl>
Onderwerp: Remdesivir

Dear 5.1.2e

I get in touch with you to ask if you have taken any action to ensure the availability of remdesivir. In Spain we have run out of doses to administer to patients and we are waiting to receive ESI vials.
We have created a working group to develop a protocol for the use of remdesivir to optimize its use together with scientific societies and my question is if you have activated mechanisms such as the compulsory license or some other or if you consider it.

Thanks in advance

Patricia Lacruz Gimeno
Directora General de Cartera Común de Servicios SNS y Farmacia
MINISTERIO DE SANIDAD
Paseo del Prado, 18-20
28071 Madrid
Teléfono: 5.1.2e
Correo: 5.1.2e @mscbs.es

original.